10X Genomics Inc (TXG) Peer Comparison

$84.20

$0.09 (0.11%)

As on 25-Sep-2026 13:38EDT

Market cap

$9,980 Mln

Revenue (TTM)

$617 Mln

P/E Ratio

--

P/B Ratio

12.1

Div. Yield

0 %

Edit

	10X Genomics Inc (TXG)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	9,980	12,560	10,497	9,770	9,983
Revenue ($ Mln)	617	1,505	6,561	2,589	785
Net Profit ($ Mln)	-75.13	160.59	-578.00	222.40	41.54
Net Margin (%)	-12.18	10.67	-8.81	8.59	5.29
RoE (%)	-9.26	10.86	-10.33	3.04	1.97
Price to Earnings	--	78.15	--	44.47	242.32
Price-To-Book	12.14	8.19	1.91	1.36	4.76

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	10X Genomics Inc (TXG)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	616.91	1,504.87	6,561.10	2,589.30	785.10
Cost of Revenue	184.88	483.98	4,473.00	1,245.50	384.30
Gross Profit	443.88	942.44	2,139.40	1,343.60	347.62
Operating Expenses	520.41	833.56	2,373.70	1,108.90	335.50
Operating Profit (EBIT)	-88.38	187.34	-285.60	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-74.89	203.83	-472.00	350.40	52.15
Provision for Tax	0.24	43.24	106.00	128.00	10.61
Profit after Tax (Net Income)	-75.13	160.59	-578.00	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	10X Genomics Inc (TXG)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	825.55	1,530.77	5,630.20	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	86.01	210.18	4,583.70	2,116.80	705.49
Current Liabilities	118.51	233.78	1,382.00	961.30	132.66
Total Liabilities	1,041.37	1,826.52	11,794.70	10,576.50	2,949.70

Assets ($ Mln)

	10X Genomics Inc (TXG)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	355.40	630.60	9,133.70	7,231.50	1,749.63
Current Assets	674.67	1,344.12	2,462.20	3,020.50	1,200.55
Total Assets	1,041.37	1,826.52	11,794.70	10,576.50	2,949.70
Total Debt*	78.80	212.71	3,697.80	1,203.70	690.94
Net Current Assets	556.16	1,110.35	1,080.20	2,059.20	1,067.90

Cashflow ($ Mln)

	10X Genomics Inc (TXG)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	136.05	238.66	623.80	532.20	117.42
Cash Flow from Investing Activities	-13.44	-404.59	-130.50	-189.70	-298.47
Cash from Financing Activities	6.80	26.53	-409.40	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	10X Genomics Inc (TXG)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-4.99	11.76	-5.43	8.98	1.79
ROE (%)	-9.26	10.86	-10.33	3.04	1.97
ROA (%)	-6.71	7.95	-4.08	2.02	1.36
EBIT Margin (%)	1.68	13.63	-4.47	-5.99	9.87
Net Margin (%)	-12.18	10.67	-8.81	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	10X Genomics Inc (TXG)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	-4.28	17.55	-1.57	1.37	16.49
EBIT Growth (%)	113.10	17.49	-129.16	-131.06	920.91
Net Profit Growth (%)	11.20	8.72	-184.08	-30.32	400.42
EPS Growth (%)	16.01	8.12	-184.11	-29.66	394.30
Book Value Growth (%)	2.26	17.33	-9.82	2.19	2.16

Valuation Ratios

	10X Genomics Inc (TXG)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-47.60	68.93	-14.68	--	189.42
Price / Book Value	2.60	8.58	1.40	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	436.68	53.25	81.94	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	10X Genomics Inc (TXG)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.00	0.00	0.65	0.11	0.26
Short term debt to equity ratio	0.01	0.01	0.01	0.06	0.01
Current Ratio	5.69	5.75	1.78	3.14	9.05
Quick Ratio	5.25	3.86	1.18	2.33	7.64
Interest Coverage	-24,962.33	157.91	-1.64	8.18	1.92

Operating Efficiency Ratios

	10X Genomics Inc (TXG)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	8.21	12.65	17.36	17.06	20.09
Asset Turnover	0.55	0.74	0.46	0.24	0.26
Receivable days	48.40	46.54	58.79	65.39	72.41
Inventory Days	128.01	331.92	64.13	221.09	146.53
Payable days	23.54	26.16	58.13	37.02	29.05
Cash Conversion Cycle	152.87	352.30	64.79	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly